"On December 16, 2014, the U. S. Food and Drug Administration approved lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroe"...
(Generic versions may still be available.)
Generally, adverse effects following the use of Mithracin (plicamycin) , especially the hemorrhagic syndrome, are dose related. Therefore, following administration of an overdose, patients can be expected to experience an exaggeration of the usual adverse effects. Close monitoring of the hematologic picture, including factors involved in the clotting mechanism, hepatic and renal functions, and serum electrolytes, is necessary. No specific antidote for Mithracin (plicamycin) is known. Management of overdosage would include general supportive measures to sustain the patient through the period of toxicity.
Mithracin (plicamycin) is contraindicated in patients with thrombocytopenia, thrombocytopathy, coagulation disorder or an increased susceptibility to bleeding due to other causes. Mithracin (plicamycin) should not be administered to any patient with impairment of bone marrow function.
Mithracin (plicamycin) may cause fetal harm when administered to a pregnant woman. Mithracin (plicamycin) is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/8/2004
Additional Mithracin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.